Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Kawasaki disease, or mucocutaneous lymph node syndrome, is a rare illness that mainly affects children under the age of 5. Symptoms include swollen glands in the neck; dry, red cracked lips; strawberry tongue; and swelling of the mucous membranes inside the mouth, nose, eyes, and throat. Diagnostic criteria include prolonged fever for more than five days and generally higher than 101.3 F, and four out of the following five findings: Bilateral conjunctival injection, oral changes such as cracked and erythematous lips and strawberry tongue, cervical lymphadenopathy, and extremity changes such as erythema. Diagnostic tools include urine tests, blood tests, and cerebrospinal fluid examination. Treatment for Kawasaki disease includes intravenous gamma globulin (IVIG), high-dose aspirin every six hours, and low-dose aspirin for at least six weeks after the fever goes down.
The Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Anviron CorpCelixir Ltd
Jazz Pharmaceuticals Plc
Oxitope Pharma BV
Rhoshan Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions